Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.02 USD | +2.87% | +0.20% | +15.94% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company has a low valuation given the cash flows generated by its activity.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The firm trades with high earnings multiples: 19.43 times its 2024 earnings per share.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.94% | 242M | C+ | ||
+1.51% | 42.75B | B | ||
+8.57% | 41.34B | B- | ||
+49.22% | 41.61B | A | ||
-12.36% | 26.59B | C | ||
+8.92% | 25.49B | B- | ||
-25.13% | 18.12B | B | ||
+29.17% | 12.24B | C+ | ||
-3.12% | 11.76B | C+ | ||
+6.35% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PBYI Stock
- Ratings Puma Biotechnology, Inc.